Although ZymoGenetics Inc. now has both independence and a $150 million war chest with which to bolster its discovery engine, the company will steer clear of becoming a target provider with high-throughput genomics capabilities, aiming instead to exploit its biology roots in protein therapeutics.

ZymoGenetics (Seattle, Wash.) had operated for the past 12 years as the primary U.S. drug discovery arm of Novo Nordisk A/S before being spun out last week in conjunction with a $150 million private financing (see B17).